Lung on a chip. The device is made using human lung and blood vessel cells and it can predict absorption of airborne nanoparticles and mimic the inflammatory response triggered by microbial pathogens. It can be used to test the effects of environmental toxins, absorption of aerosolized therapeutics, and the safety and efficacy of new drugs.

In 2021, the global Lung-on-a-chip market size will be US$ XX million and it is expected to reach US$ XX million by the end of 2027, with a CAGR of XX% during 2021-2027.
This report focuses on the global Lung-on-a-chip status, future forecast, growth opportunity, key market, and key players. The study objectives are to present the Lung-on-a-chip development in North America, Europe, Japan, China, Southeast Asia, India, etc.

Global Lung-on-a-chip Scope and Market Size
Lung-on-a-chip market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Lung-on-a-chip market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Pulmonary Inflammation
Pulmonary Infection

Segment by Application
Pharmaceutical & Biotechnology Companies
Academic & Research Institutes
Other End Users

By Region
North America
Europe
Japan
China
Southeast Asia
India

By Company
Emulate
Tissuse
Hesperos
CN Bio Innovations
Draper Laboratory
Mimetas
Nortis
Kirkstall
Cherry Biotech SAS
Else Else Kooi Laboratory
Micronit Microtechnologies B.V.